CSL: Investor R&D Briefing (CSL Behring) - Dec 3, 2016 - Anticipated initiation of P2 trial in congenital hemophilia factor VII deficiency in H2 2017; Anticipated launch for on-demand treatment and prophylaxis in hemophilia in 2021
Anticipated launch • Anticipated new P2 trial • Hemophilia
|